You are here: Home » News-IANS » Health-Medicine
Business Standard

Single injection curbs activity of Huntington's disease gene

IANS  |  London 

A single injection of a new treatment has been found to reduce the activity of the gene responsible for Huntington's disease for six months in a trial in an animal model.

Huntington's disease is a genetic disorder that causes neurological symptoms affecting movement, cognition and behaviour.

"We are extremely excited by our latest results, which show a lot of promise for treating Huntington's disease," said project lead Mark Isalan from Imperial College London.

Huntington's usually only begins to show symptoms in adulthood. There is currently no cure and no way to slow the progression of the disease. Symptoms typically progress over 10-25 years until the person eventually dies, a university statement said.

In this study, the researchers tested the efficacy of a therapeutic protein called a "zinc finger".

Huntington's disease is caused by a mutant form of a single gene called Huntingtin. The zinc finger protein works by targeting the mutant copies of the Huntingtin gene, repressing its ability to express and create harmful proteins.

In the new study involving mice, published in the journal Molecular Neurodegeneration, the injection of zinc finger repressed the mutant copies of the gene for at least six months.

In a previous study in mice, the team had curbed the mutant gene's activity for just a couple of weeks.

By tweaking the ingredients of the zinc finger in the new study they were able to extend its effects to several months, repressing the disease gene over that period without seeing any harmful side effects.

This involved making the zinc finger as invisible to the immune system as possible.

"However, while these encouraging results in mice mean that the zinc finger looks like a good candidate to take forward to human trials, we still need to do a lot of work first to answer important questions around the safety of the intervention, whether repeat treatments are effective, whether there might be longer-term side effects, and whether we can extend and increase the benefits beyond six months," Isalan said.

"If all goes well and we have further positive results, we would aim to start clinical trials within five years to see whether the treatment could be safe and effective in humans," Isalan pointed out.

--IANS

gb/vm

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, September 10 2016. 14:24 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU